Zimbabwe has declined a major US healthcare agreement worth 367 million US dollars (£272m) over five years due to the United States' demand for sensitive biological samples.
This move became public following a government memo dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the deal was "lopsided".
An official spokesperson later stated that the US was seeking genetic material for scientific study and commercial gain while was not willing to share the benefits from future medical innovations.
"We must now begin the challenging and unfortunate process of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for continued negotiations to reach a deal acceptable to all parties so the nation's critical HIV treatment initiative can continue.
Wider Background
This rejection follows a similar case in Kenya, where a court halted a related deal with the US following legal challenges were raised about the safety of citizens' medical information.
Since resuming office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
The agency had administered assistance for the American government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government deals to enhance transparency and accountability.
As per reports, 16 African countries have so far agreed to similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment via US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, with no equivalent guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Effectively, our country would provide the raw materials for scientific discovery without any assurance that the final treatments would be accessible to our citizens if a future health crisis emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting structures previously established via the international organization.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to deal with potential global health emergencies.
"This mechanism is intended to guarantee that when a nation contributes its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
The government's concerns regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how future co-operation could be designed in a manner that respects the independence and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but recommended that negotiations should continue given that a large portion of the nation's Aids initiatives relied on foreign aid.
"If specific concerns exist, such as those involving data governance or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," it said.
The situation highlights the complex tensions between accepting vital foreign assistance and protecting local interests in an increasingly data-driven world.